đ
PM Q3 2024 Earnings Call
October 22, 2024 at 12:00 AM
đ
Company
PM
Quarter
Q3 2024
Date
October 22, 2024 at 12:00 AM
Speakers
2
Word Count
~7,583
Transcript Content
Operator
Our first question comes from Bonnie Herzog with Goldman Sachs. Your line is open.
Speaker
All right. Thank you. Hi Emmanuel hope you are well? Emmanuel Babeau (CFO): Good morning, Bonnie.
Speaker
I have a question on IQOS. I wonder if you could maybe comment a little bit further on the expected volume trajectory for IQOS, shipment volume growth did decelerate to the high single-digit range in Q3 from double-digit history. So I know there were some timing impacts and seasonality. But just could you maybe update us a little bit further on that in the quarter than maybe how that will reverse in Q4. And then also hoping for more color on volume, IQOS volume that is in East Asia, which has also decelerated just the drivers of that and whether you expect shipments to improve in the region in Q4? Emmanuel Babeau (CFO): Sure, Bonnie, with pleasure, and youâre giving me the opportunity to maybe be back on the fact that when you look at IQOS, I really urge you to watch at the in-market sales, the adjusted in-market sales, which is the best proxy we can have from consumer off-take. And on that indicator, the good news was the confirmation of the reacceleration that we were expecting and we have been flagging the fact that weâre expecting accelerated momentum on IQOS in H2. And we are indeed seeing that in our Q3 adjusted in-market sales because we are almost at 15%. You were asking the question about East Asia. Actually, Japan delivered again around 14% of adjusted in-market sales. So the market for IQOS remains extremely dynamic despite the fact that we have, of course, already close to 30% market share, but we continue with strong double-digit, and that was a very good news. What happened in Q3 to explain the acceleration is, as I said, continued very strong dynamism in Japan. By the way, South Korea is also doing well. And we â I think we are showing the number in Seoul where we are nicely growing the market share. Then there was a reacceleration in Europe. And I know that we received a lot of questions, okay, how confident can you be in the fact that Europe is going to reaccelerate. We knew that we were going through this transition phase for the flavor ban. And we see the market progressively exiting the disruption of the ban with the reacceleration. Italy was, of course, during the third quarter, the country with the reacceleration and that was nice to see Italy clearly restarting on a very strong foot, the growth on IQOS. And we resumed double-digit growth on adjusted AMS in Europe in Q3. And then you have a number of other markets in the world. And I would say we see momentum here building up, which is very good news for the future. I could mention, of course, Indonesia, Saudi Arabia, Mexico, I think EU here as well. I mean, we see a number of markets where there is â and of course, Egypt, but Egypt has been now for more than a year with growth, where we see real momentum emerging behind IQOS which, of course, weâre just at the beginning. So a lot of potential but that is very encouraging on the fact that we have nice growth relay outside Japan and EU for the future. So thatâs really what weâve seen in Q3. Now you have the question on the shipment. Well, weâve been flagging the fact that shipment would be â trajectory would be disconnected from the consumer off-take. We had some very strong growth in the first two quarters, which was notably driven by comparison year-on-year. There was, of course, a Red Sea disruption that generated some shipments in the first part of the year. And therefore, today, we have shipments that are a bit lower for the third quarter than the adjusted IMS. And weâre just, if you want, here for the nine months going to a situation where gradually, we are equalizing adjusted IMS and the shipments. So thatâs what we are seeing. And in Q4, weâre going to be with more equalization because weâre going to be facing two elements. The first one, regarding the Red Sea disruption, weâre going to have some reversal in Q4, so that will play negatively on the shipment. And we also are facing some high comps last year as we are building inventory to prepare the transition for the flavor ban in Europe. So thatâs a high comps in time of shipments last year. But at the end of the day, you should expect adjusted IMS and shipments through a certain period to evolve in parallel way. And as we said, we continue to expect, for Q4, a renewed momentum on consumer off-take or what we call adjusted market sales, which is really what matters. Thatâs what is important because thatâs what is talking about the health of IQOS.
Speaker
Yes. Okay. All of that makes sense and itâs really helpful. Thank you. And then maybe a second question on ZYN. So the supply constraints appear to be easing, which is great. So I just wanted to confirm, Emmanuel, that you are on track to fully restore supply levels this quarter? Or is there a chance this bleeds into maybe early next year? And then when this happens, how quickly do you expect ZYN to recapture some of the lost market share? And just curious what role will potential stepped up promos play, I guess, if at all? How are you thinking about that? Thank you. Emmanuel Babeau (CFO): Sure. On ZYN, Bonnie, we said somewhere in Q4, we will have the supply to the market, meeting consumer demand, which to clarify again, doesnât mean that we will have fully been replenishing all level of inventory. Here at that point, we believe for what we can assess of the consumer demand that what we bring to the trade will correspond to what the consumer will take from the trade, will buy from the trade. But then there will certainly be â and Iâm not able to tell you what is going to happen during this quarter. But I think we are still in this perspective then, but thatâs probably more for 2025, there will be a replenishment of the out-of-stock situation. And we will gradually â but thatâs going to happen only gradually probably through 2025, put back the level of inventory to what it should be normally and that certainly will take some months as we continue to increase the capacity. Remember, we said that for the full year 2025, we are targeting an overall capacity of around 900 million can. Of course, that is a capacity that we are going to build gradually. It wonât be there at the beginning of the year. And I would say the replenishment and being back to a fully normal situation is going to happen only gradually through 2025. And of course, when we can be more specific about that, we will be more specific with the topic. So thatâs for supply. When it comes to regaining share, so what weâve seen is that, in fact, when the availability of ZYN went down, weâve seen the category slowing down because, obviously, it seems that a number of buyer of ZYN are not intending to buy another brand. And therefore, when they donât find their ZYN, they are maybe producing or consuming something else. But that probably has been slowing down a bit the category. We will see how we gradually recover. Weâve seen in the second part of the Q3, some improvement sequentially on our market share, which is good news. We believe that we have some positive outlook as we regain availability for the product, but itâs difficult to be more specific than that at that stage.
Speaker
All right, thank you. I will pass it on. Emmanuel Babeau (CFO): Thank you.
Operator
Thank you. And our next question comes from Gaurav Jain with Barclays. Your line is open.
Speaker
Hi. Good morning, Emmanuel. Emmanuel Babeau (CFO): Good morning, Gaurav.
Speaker
A couple of questions from me. So just looking at the cigarette markets internationally, your pricing guidance, you have increased 8% to 9% and yet volumes are positive. The factors that youâre mentioning why volumes are so strong, which is lack of SBD in Brazil and Turkey, lack of smuggling probably from Russia, Belarus, all these countries. They should continue in FY 2025. So shouldnât then FY 2025 also be a pretty strong year for cigarette volumes and pricing internationally. And within that context, can you also touch on if there are any disruptive excise tax hike happening in the next few months? Emmanuel Babeau (CFO): Thanks, Gaurav, for your question. So I donât want to enter now into commenting 2025. And of course, in due course, weâll share with you on the outlook for the year. I think what we are seeing in 2024 is well-identified. We talk about a number of markets where smoke-free products are not allowed. Sometimes you have increasing the prevalence, sometimes you have demographics that are playing positively for the consumption of cigarettes. I think India is a clear market when it comes to demographic, for instance. And itâs difficult to say how long all that is going to play and whatâs going to be the continuation of this trajectory. I think we need to be a bit cautious on the outlook, but itâs true that I cannot say that everything will finish on the 31st of December 2024. So we donât know whatâs going to be the trajectory in 2025. What is certainly good is to see that we are able to actually grow volume, grow share of segment and, at the same time, increase price in a very dynamic manner, which is a tribute to the strength of our brand, and itâs true that the 9.7% in Q3 was a remarkable price increase. Donât take that for Q4 as a guidance, but that was very good in Q3. And that shows that in this category, where I think weâve been clear on our objective, which is really to maximize the performance on combustible in order to accompany and help the fastest transition to smoke-free. I think this strategy on combustible is working and delivering. And remember, we also said that in 2025, we expect a number of positive evolution for combustible cigarettes when it comes to cost of goods, where weâll have a lower level of headwinds. So there will be continuation of price increase in the future without a doubt. Nevertheless, donât take the 8% to 9% as the guidance for the future. We always said that we were more mid-single digits on the medium term. And we should see less headwind on cost of goods, which is probably good for the combustible cigarette profitability. On excise tax, at that stage, there is nothing really material I can report, I would say, traditional discussion, but weâre still a bit early. You know that many, many decisions are made in November, if not in December, so probably weâll know more at the end of the year. But so far, I would say nothing specific or unusual to flag.
Speaker
Sure. Thank you. And my second question is on your e-cigarette comments. So what you told us is that you have shipped 1.2 billion sticks year-to-date. And if I understand correctly, you are using the conversion factor is 1 ml is 10 sticks. And if I assume 1 pod is 0.7 ml then youâre shipping 160 million pods. So that would suggest that your e-cigarette revenue run rate is $300 million to $400 million, at which your contribution basis breakeven. So am I ballpark correct and all these numbers are done? Emmanuel Babeau (CFO): Yes, I can certainly confirm that 1 milliliter equates to 10 sticks, 10 cigarettes. Thatâs the equivalent. And I would say that ballpark, Iâm not going to confirm exactly, but you are not million miles away from the reality on volumes. On revenue, I wonât comment.
Speaker
Sure, thank you so much. Emmanuel Babeau (CFO): Thank you.
Operator
Thank you. Our next question comes from Faham Baig with UBS. Your line is open.
Speaker
Hi, Emmanuel. Hi, James. Thanks for taking my questions. A couple from me, please. I want to start with vapor, particularly because one of your peers highlighted that in Europe vapor is seeing greater success in sort of fully converting smokers than heated tobacco. I know Iâve asked this before, but I wanted to get your latest thoughts on this topic as well as whether youâre seeing an acceleration in vapor adoption as you sort of roll out VEEV in several markets. Emmanuel Babeau (CFO): Sure, Faham. With pleasure. So on greater success from vaping in convincing smoker, we donât see any of that. The experience is very different. Itâs quite obvious that versus heat-not-burn, heating a liquid, which has no tobacco is delivering a very, very different experience. And I think all markets are pointing to the fact that there is clearly a much, much higher and much better conversion from smokers to heat-not-burn into vaping. And I think the success of IQOS is brightly illustrating that, I have to say, Iâm not coming back on the performance on IQOS. I donât think we are really seeing an acceleration in the adoption of vaping. The vaping market, the vaping category is impacted today by many, many regulation evolution or potential evolution. We know that one of the problems of the vaping category is that you have a responsible player going for fancy flavor, unacceptable marketing behavior that can generate underage consumption that can be creating some disruption. We know that notably the disposable category has been generating some of that. But if you look at the â what we can say of the legal age nicotine user, I donât think that we can report any acceleration that would be meaningful from vaping. Regarding the nicotine part in the U.S., and your question on what we do, can you first allow me a general comment? I think that PMI is at the forefront, at the very forefront when it comes to fighting illicit trade. And that is true for the U.S., that is true everywhere in the world. We commit huge resources, I mean, investments in fighting illicit trade, working with authorities, regulators in many countries to do that. And for us, itâs a very, very important battle, a very important fight. So, the U.S. make no exception. And yes, when we are aware of illicit, when we are aware of product infringing, potentially our patent, we are acting. I think that in my remarks, I signaled some of the things that we do. When we identified the sources that are potentially outside the U.S. we could go to even terminating sales to these sources. I said it. We are working with distributors. It can be informing, creating the awareness for illicit product writing to distributor. It can be sending cease and desist letter to distributor retail where we see an issue. And we do that on our own or working with the regulator, as I said, in the U.S. like everywhere in the world. So you can be sure that we take that extremely seriously.
Speaker
Thanks, Emmanuel. Emmanuel Babeau (CFO): Thank you very much.
Operator
Our next question comes from Priya Ohri-Gupta with Barclays. Your line is now open.
Speaker
Hi Emmanuel, thank you so for receiving me. Emmanuel Babeau (CFO): Hi, great.
Speaker
Just two quick ones from me. First, it does look like you modestly sort of took down the top end of your potential deleveraging for this year by a little bit if you could address sort of what drove that? And then secondly, you do have a fairly sizable amount of maturities over the course of 2025. Any thoughts on pulling some of that refinancing forward into the remainder of this year, just given where markets are opportunistically? Thank you. Emmanuel Babeau (CFO): Yes, taking these two questions with pleasure. So, on the slightly and very modestly narrowing the guidance for deleveraging, itâs because of the euro strength at the end of September that was â because as you know, we have a significant part of the debt in euro and therefore, when the euro is going up versus the dollar, that can have a kind of one-off element because we always have this discrepancy between an EBIT that is calculated on an average rate for the year when the debt is going to be calculated on the spot on the 31 of December. So weâll see where we land. But the trajectory is clear. And you may have seen that at the end of the third quarter, we have generated cash flow of $8.2 billion, and that is simply $2.3 billion above the cash flow generation at the end of Q3 2023. So, we are highly generating cash, of course, on the back of a very strong momentum in the business, but thatâs good news. Yes, I mean, I am certainly not going to discard the possibility for us to be active on the refinancing market in the coming months. I am not going to elaborate now on that, and we have a number of options that are open to us. But you can be sure that we are already working on how to put in place the best refinancing again in the coming months for PMI.
Speaker
Thank you so much. Emmanuel Babeau (CFO): Thank you.
Operator
Thank you. Our next question comes from Gaurav Jain with Barclays. Your line is open.
Speaker
Guys, just a follow-up on the Canadian litigation settlement. Would these payments be tax-deductible? And when do you think something final will happen in this long run in sort of COVID case? Emmanuel Babeau (CFO): Thank you, Gaurav. On the Canada litigation, so you have what we can say at that stage in our press release that we have issued last week. Itâs too preliminary. And as I said, I am not able to tell you whether itâs going to be tax-deductible. Of course, as soon as we know we will let you know. But for the time being, I am not able to say. And as you may have seen in our release, where we shared what we can share at that stage, there are still a number of elements in this proposed solution put on the table by the mediators to be finalized. And of course, once we have the final terms, we will come back to you with this answer, of course, but also all the question on whatâs going to be the impact for PMI of a final settlement.
Speaker
Thank you so much. Emmanuel Babeau (CFO): Thank you.
Operator
Thank you. I am showing no further questions at this time. I would now like to turn it back to James Bushnell for closing remarks. James Bushnell (Head of Investor Relations): Thank you for joining us today. Please reach out to the Investor Relations team if you have any follow-up questions. I am wishing you a good rest of the week and earnings season. Emmanuel Babeau (CFO): Look forward to speaking to you soon. Thank you. Have a great day.
Operator
This concludes todayâs conference call. Thank you for participating. You may now disconnect.
Need more earnings data?
Explore more earnings information and financial data for PM
Transcript sourced from Financial Modeling Prep (FMP)